Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
52
PharmaCompass offers a list of Ipragliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ipragliflozin manufacturer or Ipragliflozin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ipragliflozin manufacturer or Ipragliflozin supplier.
PharmaCompass also assists you with knowing the Ipragliflozin API Price utilized in the formulation of products. Ipragliflozin API Price is not always fixed or binding as the Ipragliflozin Price is obtained through a variety of data sources. The Ipragliflozin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ipragliflozin-L-proline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ipragliflozin-L-proline, including repackagers and relabelers. The FDA regulates ipragliflozin-L-proline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ipragliflozin-L-proline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ipragliflozin-L-proline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ipragliflozin-L-proline supplier is an individual or a company that provides ipragliflozin-L-proline active pharmaceutical ingredient (API) or ipragliflozin-L-proline finished formulations upon request. The ipragliflozin-L-proline suppliers may include ipragliflozin-L-proline API manufacturers, exporters, distributors and traders.
click here to find a list of ipragliflozin-L-proline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ipragliflozin-L-proline DMF (Drug Master File) is a document detailing the whole manufacturing process of ipragliflozin-L-proline active pharmaceutical ingredient (API) in detail. Different forms of ipragliflozin-L-proline DMFs exist exist since differing nations have different regulations, such as ipragliflozin-L-proline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ipragliflozin-L-proline DMF submitted to regulatory agencies in the US is known as a USDMF. ipragliflozin-L-proline USDMF includes data on ipragliflozin-L-proline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ipragliflozin-L-proline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ipragliflozin-L-proline suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ipragliflozin-L-proline Drug Master File in Korea (ipragliflozin-L-proline KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ipragliflozin-L-proline. The MFDS reviews the ipragliflozin-L-proline KDMF as part of the drug registration process and uses the information provided in the ipragliflozin-L-proline KDMF to evaluate the safety and efficacy of the drug.
After submitting a ipragliflozin-L-proline KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ipragliflozin-L-proline API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ipragliflozin-L-proline suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ipragliflozin-L-proline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ipragliflozin-L-proline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ipragliflozin-L-proline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ipragliflozin-L-proline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ipragliflozin-L-proline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ipragliflozin-L-proline suppliers with NDC on PharmaCompass.
ipragliflozin-L-proline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ipragliflozin-L-proline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ipragliflozin-L-proline GMP manufacturer or ipragliflozin-L-proline GMP API supplier for your needs.
A ipragliflozin-L-proline CoA (Certificate of Analysis) is a formal document that attests to ipragliflozin-L-proline's compliance with ipragliflozin-L-proline specifications and serves as a tool for batch-level quality control.
ipragliflozin-L-proline CoA mostly includes findings from lab analyses of a specific batch. For each ipragliflozin-L-proline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ipragliflozin-L-proline may be tested according to a variety of international standards, such as European Pharmacopoeia (ipragliflozin-L-proline EP), ipragliflozin-L-proline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ipragliflozin-L-proline USP).
